Antioxidant Phytochemicals in Drug Discovery

A special issue of Antioxidants (ISSN 2076-3921). This special issue belongs to the section "Natural and Synthetic Antioxidants".

Deadline for manuscript submissions: 30 June 2024 | Viewed by 1180

Special Issue Editor


E-Mail Website
Guest Editor
Laboratory of Microbial & Oncology, Laboratory of Presymptomatic Medical Pharmacology, Faculty of Pharmaceutical Sciences, Sojo University, Kumamoto, Japan
Interests: antioxidants; inflammation; advanced glycation end-products; bioactive compounds; infections; antimicrobials; bacterial biofilms; polymeric micelle nanocarrier

Special Issue Information

Dear Colleagues,

Cancer remains the leading cause of human death in the world. Cancer is a multifactorial disease and many events are involved in the initiation and progression of cancer, in which inflammation is one of the major carcinogens. It is well known that chronic inflammation triggers DNA mutation and carcinogenesis via the generation of reactive oxygen species (ROS). Thus, anti-inflammatory agents are considered useful for cancer prevention. It has long been known that many natural products exhibit versatile biological activities, including anti-inflammation effects, activation of innate immunity, and anticancer effects. Thus, for centuries, natural products have been used as medicines for many diseases in which inflammation and cancer are the major targets. The development and utilization of natural products for controlling inflammatory diseases and cancer have been attracting more and more attention and have become a promising research field. This Special Issue will publish original research papers as well as reviews and clinical studies on the benefits of natural products focusing on anti-inflammation, the activation of innate immunity, and anticancer effects.

Prof. Dr. Kazumi Yokomizo
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antioxidants is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • natural products
  • anticancer effect
  • anti-inflammation
  • activation of innate immunity
  • antioxidants

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

14 pages, 3891 KiB  
Article
Stigmasterol Exerts an Anti-Melanoma Property through Down-Regulation of Reactive Oxygen Species and Programmed Cell Death Ligand 1 in Melanoma Cells
by Na-Ra Han, Hi-Joon Park, Seong-Gyu Ko and Phil-Dong Moon
Antioxidants 2024, 13(3), 380; https://doi.org/10.3390/antiox13030380 - 21 Mar 2024
Viewed by 815
Abstract
Cancer immunotherapy as a promising anti-cancer strategy has been widely studied in recent years. Stigmasterol (STIG), a phytosterol, is known to have various pharmacological effects, including anti-inflammatory effects. However, the pharmacological role of STIG on melanoma immunotherapy has not been investigated. The present [...] Read more.
Cancer immunotherapy as a promising anti-cancer strategy has been widely studied in recent years. Stigmasterol (STIG), a phytosterol, is known to have various pharmacological effects, including anti-inflammatory effects. However, the pharmacological role of STIG on melanoma immunotherapy has not been investigated. The present study demonstrates the anti-melanoma potency of STIG through the regulation of PD-L1 levels. The results reveal that STIG reduces reactive oxygen species (ROS) levels induced by hydrogen peroxide and increases glutathione levels decreased by α-MSH in B16F10 cells. Moreover, STIG significantly decreases melanin content and tyrosinase activities elevated by α-MSH. It also suppresses nitric oxide production induced by α-MSH. Additionally, STIG induces apoptosis with the up-regulation of PARP activation. STIG inhibits IFN-γ-induced PD-L1 expression and STAT1 phosphorylation levels. STIG also reverses the up-regulation of PD-L1 and phosphorylated STAT1 levels augmented by cisplatin, and STIG enhances CD8(+) T-cell-mediated cell death against B16F10 cells. These findings represent the first evidence of pro-apoptotic activity of STIG on melanoma cells through the down-regulation of ROS and PD-L1 pathways. Therefore, STIG may be an effective candidate for melanoma immunotherapy. Full article
(This article belongs to the Special Issue Antioxidant Phytochemicals in Drug Discovery)
Show Figures

Figure 1

Back to TopTop